Gilead Sciences was founded in 1987 and is headquartered in Foster City, US

CEO

COO

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 2 other locations

Foster City, US (HQ)

333 Lakeside Dr

Branford, US

36 E Industrial Rd

Fremont, US

7601 Dumbarton Cir

Oceanside, US

4049 Avenida De La Plata

San Dimas, US

650 Cliffside Dr

Seattle, US

199 E Blaine St

Gilead Sciences's revenue was reported to be $30.4 b in FY, 2016

USD

## Revenue (Q2, 2017) | 7.1 b |

## Gross profit (Q2, 2017) | 6 b |

## Gross profit margin (Q2, 2017), % | 84% |

## Net income (Q2, 2017) | 3.1 b |

## EBIT (Q2, 2017) | 4.3 b |

## Market capitalization (22-Dec-2017) | 95.9 b |

## Cash (30-Jun-2017) | 8.7 b |

Gilead Sciences's current market capitalization is $95.9 b.

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Revenue | 11.2 b | 24.9 b | 32.6 b | 30.4 b |

## Revenue growth, % | 122% | 31% | (7%) | |

## Cost of goods sold | 2.9 b | 3.8 b | 4 b | 4.3 b |

## Gross profit | 8.3 b | 21.1 b | 28.6 b | 26.1 b |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 2.8 b | 5 b | 6.5 b | 6 b | 7.6 b | 8.2 b | 8.3 b | 7.8 b | 7.8 b | 7.5 b | 6.5 b | 7.1 b |

## Cost of goods sold | 681.9 m | 813.2 m | 924.7 m | 987.3 m | 882 m | 998 m | 1.1 b | 1.2 b | 864 m | 1.1 b | 957 m | 1.1 b |

## Gross profit | 2.1 b | 4.2 b | 5.6 b | 5.1 b | 6.7 b | 7.2 b | 7.2 b | 6.6 b | 6.9 b | 6.4 b | 5.5 b | 6 b |

## Gross profit Margin, % | 75% | 84% | 86% | 84% | 88% | 88% | 87% | 85% | 89% | 85% | 85% | 84% |

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 2.1 b | 10 b | 12.9 b | 8.2 b |

## Inventories | 2.1 b | 1.4 b | 2 b | 1.6 b |

## Current Assets | 7.3 b | 17.7 b | 24.8 b | 20.4 b |

## PP&E | 1.2 b | 1.7 b | 2.3 b | 2.9 b |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 2 b | 6.4 b | 8.7 b | 6.2 b | 10.6 b | 7.4 b | 14 b | 6.3 b | 6.5 b | 9.8 b | 10.3 b | 8.7 b |

## Accounts Receivable | 2 b | 3.2 b | 3.4 b | 2.9 b | 4.8 b | 5.3 b | 6.1 b | |||||

## Inventories | 1.9 b | 2.1 b | 2.1 b | 1.9 b | 1.9 b | 2 b | 2 b | 1.9 b | 1.9 b | 1.9 b | 1.5 b | 1.4 b |

## Current Assets | 7 b | 13 b | 15.5 b | 12.6 b | 20.1 b | 18.1 b | 25.9 b | 19.3 b | 18.4 b | 21.4 b | 21.4 b | 28.6 b |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | 3.1 b | 12.1 b | 18.1 b | 13.5 b |

## Accounts Receivable | (315.3 m) | (2.6 b) | (1.4 b) | 1.2 b |

## Inventories | (343.1 m) | 143 m | (855 m) | (488 m) |

## Accounts Payable | (97.7 m) | (289 m) | 226 m | 47 m |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | 785.2 m | 2.2 b | 3.7 b | 2.7 b | 4.3 b | 8.8 b | 13.4 b | 3.6 b | 7.1 b | 10.4 b | 2.7 b | 5.8 b |

## Depreciation and Amortization | 75 m | 116 m | 42 m | 85 m | 129 m | 49 m | 103 m | |||||

## Accounts Receivable | (810 m) | (1.6 b) | (191 m) | 190 m | 770 m | 537 m | 118 m | |||||

## Inventories | (634 m) | (659 m) | (14 m) | (97 m) | (274 m) | (5 m) | (14 m) |

Y, 2017 | |
---|---|

## Financial Leverage | 2.6 x |

FY, 2016 | |
---|---|

## Countries | 30 |

## Products | 25 |

## Phase III Trials | 6 |

## Phase II Trials | 12 |

Acquired Company | Date | Deal Size |
---|---|---|

Kite Pharma | August 28, 2017 | $11.9 b |

Source: 349 public H-1B filings from Gilead Sciences

Search term - Gilead Sciences